Catherine Skari

Splenectomy as Treatment for Primary Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia (wAIHA) occurs when the body’s immune system mistakenly produces antibodies that attack and destroy its own…

Read More »

WHAT YOU NEED TO KNOW | EMA Recommends Suspension of Pfizer’s Sickle Cell Disease Drug Oxbryta

Oxbryta, which was designed to treat sickle cell disease, has been a crucial medication for patients with mild-to-moderate symptoms. Approved…

Read More »

Stroke Risk Rises in People with Sickle Cell Disease Despite Treatment Guidelines

A new study reveals that stroke rates are continuing to rise among both adults and children living with sickle cell…

Read More »

APLASTIC ANEMIA | Hetrombopag Achieves Significant Hematological Responses in Newly Diagnosed Patients

In this study, newly diagnosed patients with transfusion-dependent non-severe aplastic anemia (TD-NSAA) were initially treated with either a combination of…

Read More »

THALASSAEMIA WEBINAR FOR ASEAN & OCEANIA HEALTHCARE PROFESSIONALS | 21 October 2024

This webinar provides a unique opportunity to exchange scientific knowledge and gain clinically relevant insights on the latest developments in…

Read More »

UNITING EXPERTS | Highlights from the 1st Nordic Red Blood Cell Meeting

The meeting, organised by the Danish Red Blood Cell Centre of the Copenhagen University Hospital – Rigshospitalet, and led by…

Read More »

ANNUAL REPORT 2023 | Unveiling TIF’s Impactful Achievements

In 2023, TIF enhanced its advocacy efforts with the WHO to advance the UN Sustainable Development Goals 2030 and universal…

Read More »

WORLD PATIENT SAFETY DAY 2024 | Get It Right, Make It Safe!

This year the theme is “Improving diagnosis for patient safety” with the slogan “Get it right, make it safe!”, highlighting…

Read More »

REGULATORY APPROVAL | PiaSky Becomes the First Monthly Treatment for PNH in the EU

Paroxysmal Nocturnal Haemoglobinuria (PNH) is a rare and life-threatening blood condition where red blood cells are destroyed by the complement…

Read More »

ACCESS TO INNOVATION | UK Greenlights Gene-Editing Therapy Casgevy for β-Thalassaemia Treatment

This development opens new treatment avenues for an estimated 460 patients aged 12 and above in England who rely on…

Read More »